AUS
NZ
UK
CA
USA
IND
Lumos Diagnostics Holdings Limited (ASX:LDX) has achieved a key milestone as part of its development agreement to produce a next-generation foetal fibronectin (fFN) test. This diagnostic tool is designed to predict a pregnant woman's risk of pre-term delivery and is being developed in collaboration with Hologic Inc. (NASDAQ:HOLX), a prominent player in the women’s health industry.
This development milestone marks the completion of Phase 2 in Lumos’s agreement with Hologic, under which Lumos is responsible for developing an enhanced version of Hologic’s existing fFN test. The test aims to detect the presence of the foetal fibronectin protein, a biomarker linked to premature birth risk. This collaboration aligns with Lumos’s focus on point-of-care diagnostics, with the potential to provide critical insights for expecting mothers and healthcare providers.
The fFN protein acts as a biological adhesive, keeping the foetus attached to the uterus. If the protein is detected in vaginal secretions late in pregnancy, it indicates an increased risk of pre-term birth. Given the urgency of premature birth detection and prevention, this diagnostic test could have a profound impact on maternal healthcare. The U.S. market alone sees 2.5 million tests annually, with each test reimbursed at a rate of US$64.41.
Phased Development Plan
Lumos’s development agreement with Hologic is structured in three phases, with total milestone payments reaching US$4.7 million. Each phase focuses on different aspects of the product’s evolution:
- Phase 1: Product Definition and Planning (Completed, US$400,000)
- Phase 2: Assay Feasibility (Milestone Reached, US$600,000)
- Phase 3: System Prototype Delivery (Future Milestone, US$3.7 million)
Phase 2 of the project centers on demonstrating that Lumos’s assay can effectively detect the fFN biomarker. The company recently received US$300,000 for successfully completing the first milestone in this phase. This milestone is a critical step towards the development of the test, with Lumos continuing to work on the remaining milestones.
Key Market Potential
The market for pre-term diagnostic tests is significant, particularly in the United States. The fFN test represents the largest segment within this market. Given the healthcare demand for early detection of premature birth risks, this diagnostic tool is highly sought after by both healthcare providers and expecting families. The partnership between Lumos and Hologic, combined with Lumos’s proprietary reader platform, positions both companies to capitalize on the growing need for effective pre-term diagnostic solutions.
The adaptation of the fFN test to Lumos’s proprietary technology platform is expected to further enhance the test’s connectivity and usability. This will likely make it easier for healthcare providers to integrate the diagnostic tool into clinical workflows, potentially improving patient outcomes.
Strategic Investment by Tattarang
In a related development, Lumos recently announced a significant change in its shareholding structure. Tenmile, a wholly owned subsidiary of Andrew and Nicola Forrest’s private investment vehicle Tattarang, has acquired 45 million shares in Lumos, representing a 9.3% stake in the company. The shares were acquired from Planet Innovation, marking Tenmile as the largest shareholder in Lumos. This strategic investment could provide additional capital and backing for Lumos as it continues its development efforts in diagnostic technologies.
Future Outlook
Lumos Diagnostics is well-positioned to make a substantial impact in the field of maternal healthcare diagnostics. The successful completion of Phase 2 under the development agreement with Hologic is a significant step toward bringing the next-generation fFN test to market. The company’s strategic partnerships and investments further strengthen its potential for long-term success in the diagnostic space.
With the pre-term diagnostic test market growing and the increasing demand for advanced healthcare solutions, Lumos’s collaboration with Hologic is poised to deliver meaningful advancements in this critical area of maternal health. As the company continues to achieve its milestones, further developments in the diagnostic technology space are expected to emerge, positioning Lumos as a leader in point-of-care diagnostics.
Conclusion
The progress of Lumos Diagnostics in developing the fFN test for premature birth, alongside its strategic investment from Tenmile, places the company on a growth trajectory. Meanwhile, Johns Lyng’s acquisition of a controlling stake in Keystone strengthens its presence in the restoration and building services industry. Both companies demonstrate forward-thinking strategies aimed at driving growth and innovation in their respective markets.
